Land: Kanada
Tungumál: enska
Heimild: Health Canada
OXYBUTYNIN CHLORIDE
AVANSTRA INC
G04BD04
OXYBUTYNIN
5MG
TABLET
OXYBUTYNIN CHLORIDE 5MG
ORAL
100
Prescription
Antimuscarinics
Active ingredient group (AIG) number: 0114692001; AHFS:
CANCELLED POST MARKET
2014-08-21
PRODUCT MONOGRAPH AVA-OXYBUTYNIN (Oxybutynin Chloride) Tablets, USP ANTICHOLINERGIC / ANTISPASMODIC AGENT AVANSTRA INC. DATE OF PREPARATION: 10761 – 25th NE, Suite 110, Building “B” February 17, 2011 Calgary, Alberta T2C 3C2 Control # 144956 [1] PRODUCT MONOGRAPH AVA-OXYBUTYNIN (Oxybutynin Chloride) Tablets, USP THERAPEUTIC CLASSIFICATION Anticholinergic / Antispasmodic Agent ACTION AND CLINICAL PHARTMACOLOGY Oxybutynin chloride is a tertiary amine anticholinergic agent which exerts anti-muscarinic as well as direct antispasmodic action on smooth muscle. In vitro studies have shown that its anticholinergic effects are weaker than those of atropine, but that it possesses greater antispasmodic activity. No blocking effects occur at skeletal neuromuscular junctions or in autonomic ganglia (no antinicotinic effects). In addition to its smooth muscle relaxing effects, oxybutynin chloride exerts an analgesic and a local anesthetic effect. In animal studies the central nervous system and cardiovascular actions of oxybutynin chloride were shown to be similar to, but weaker than, those of atropine. Oxybutynin chloride relaxes bladder smooth muscle. In patients with uninhibited neurogenic and reflex neurogenic bladder, cystometric studies have demonstrated that oxybutynin chloride increases bladder (vesical) capacity, diminishes the frequency of uninhibited contractions of the detrusor muscle, and delays the initial desire to void. Oxybutynin chloride thus decreases urgency and the frequency of both incontinent episodes and voluntary urination. These effects are more consistently improved in patients with uninhibited neurogenic bladder. Oxybutynin chloride is readily absorbed from the gastrointestinal tract. The onset of action is approximately one hour after an oral dose and its duration 6 to 10 hours. [2] Comparative Bioavailability A two-way, single-dose, open-label, randomized crossover bioavailability study in 18 normal male volunteers was conducted to evaluate the relative bioavailability of a 10 mg dose of AVA Lestu allt skjalið